Phase 3 N=306 Addiction Treatment in Russia: Oral vs. Naltrexone Implant
Heroin Dependence · Opioid-Related Disorders
Primary: Retention Without Relapse to Heroin Addiction (Measured at Month 6) — 54; 16; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=55 Memantine as a Supplement to Naltrexone in Treating Heroin Dependence
Opioid Dependence · Heroin Dependence
Primary: Opiate Use Measured by Urine Toxicology Results — 9; 10 Percent of total urine samples
Phase 2 N=10 Acute and Short-term Effects of Cannabidiol Admin on Cue-induced Craving in Drug-abstinent Heroin Dependent Humans
Opiate Addiction
Primary: Changes in Cue-Induced In-Clinic Craving (From Baseline to Post-cue or Post-neutral - Via the Visual Analog Scale for Craving (VASC) — 2.67; 0.83; -0.33; -0.17 units on…
Phase 2 N=42 Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans
Opiate Addiction
Primary: Changes in Cue-Induced In-Clinic Craving (From Baseline to Post-cue (30 Minutes), and From Test Day 1 Through Test Day 4 (1 Week)) - Via the Visual Analog Scale for…
N/A N=240 Prevention of OUD: The HOME Project (Housing, Opportunities, Motivation and Engagement)
Substance Use
Primary: Frequency (% Days) of Opioid Use in Prior 3 Months — 0; 0 % days opioid use
Phase 2 N=81 Memantine and Naltrexone Treatment for Opioid Dependence
Opioid Dependence
Primary: Retention in Treatment — 7; 5; 6 participants — p=0.32
N/A N=329 Models of Screening, Brief Intervention With a Facilitated Referral to Treatment (SBIRT) for Opioid Patients in the Emergency Department
Opiate Addiction
Primary: Self-reported Engagement in Formal Substance Abuse Treatment at 30 Days (Verified by Contact With the Treatment Program) — 4.99; 5.67; 3.71 Mean Number of Outpatient…
Phase 4 N=19 Buprenorphine and Methadone for Opioid-dependent Chronic Back Pain Patients
Low Back Pain
Primary: Analgesia — 36.3; 71.8 units on a VAS scale — p=0.097
Phase 4 N=12 A Comparison of the Addiction Liability of Hydrocodone and Sustained Release Morphine
Chronic Pain
Primary: 3 Scores on the Addiction Research Center Inventory (ARCI) — 7.6; 5.4; 5.2; 3.3 scores on a scale
Phase 2 N=156 Dronabinol Treatment for Marijuana Addiction
Marijuana Abuse
Primary: Proportion of Patients Abstinent From Marijuana During Weeks 7 and 8 of the Trial — 14; 12 participants
N/A N=87 Effectiveness of Opiate Replacement Therapy Administered Prior to Release From a Correctional Facility - 1
HIV Prevention · Opioid-Related Disorders
Primary: Treatment Engagement — 23; 11; 6 participants — p=<0.001
Phase 4 N=188 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED)
Opiate Dependence · Drug Dependence · Substance Dependence
Primary: Responders at Day 3 — 85; 85; 8; 9 Participants
Phase 2 N=12 Oxytocin Treatment of Opioid Dependence
Opioid Dependence · Opioid Withdrawal
Primary: Area Under the Curve (AUC) in COWS Total Score on Days 1 to 5 Inclusive — 4.2; 3.4 Average COWS score * hours
N/A N=312 Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings
Opioid Dependence · Addiction · HIV/AIDS
Primary: TB Treatment Completion Rates in Prison — 114; 127 Participants — p=0.08
N/A N=533 A Digital Intervention to Prevent the Initiation of Opioid Misuse in Adolescents in School-based Health Centers
Opioid Misuse
Primary: Percentage Reporting 'Great Perceived Risk of Harm' From Opioid Misuse — 66; 53 Participants
N/A N=98 A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment
Opiate Dependence
Primary: Percentage of Months in Methadone Treatment — 81; 82; 88 percent of months in methadone treatment — p=0.60
Phase 4 N=256 Project OOPEN: Opioid Overdose Prevention, Education and Intervention
Opioid Overdose
Primary: Rate of Fatal Opioid Overdose — 2; 6 Participants
Phase 3 N=653 Prescription Opioid Addiction Treatment Study (POATS)
Opiate Dependence · Substance-related Disorders · Opioid-related Disorders
Primary: The Number of Participants Attaining Successful Opioid Use Outcome by Counseling Condition at End of Phase 1 — 19; 24 participants
Phase 2 N=72 CURE Addiction Center of Excellence: Brain Mechanisms of Relapse and Recovery
Prescription Opiate/Medication Dependence
Primary: Illicit-positive Urines During Treatment and Follow-up — 0; 0; 1; 1 Participants
N/A N=78 Stress, Distress Intolerance, and Drug Dependence
Substance Dependence
Primary: Percentage of Positive Toxicology Swabs for Illicit Substances — 81.3; 79.1; 86.2; 82.3 percentage of positive toxicology screen
N/A N=133 5HT3 Antagonists to Treat Opioid Withdrawal and to Prevent the Progression of Physical Dependence
Opioid Withdrawal · Physical Dependence
Primary: Change in Objective Opioid Withdrawal Score (OOWS) From Baseline (Prevention of Opioid Withdrawal) — 3.6; 3.6 units on a scale — p=0.87
N/A N=31 Efficacy of Varenicline in Methadone-Stabilized Cocaine Users
Cocaine Dependence · Nicotine Dependence
Primary: Proportion of Cocaine Positive Urine Tests Per Week — .57; .58 Proportion of cocaine positive — p=0.84
N/A N=29 Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.
Opioid-use Disorder
Primary: Treatment Retention — 5; 5 Participants — p==0.87
Phase 3 N=211 Methadone Maintenance for Prisoners
Heroin Addiction
Primary: Treatment Retention in the Community — 23.1; 91.3; 166.0 Days in community treatment
Phase 3 N=74 Smoking Cessation & Opioid Dependence Treatment Integration
Smoking Cessation · Opioid Related Disorders
Primary: Recruitment, Assignment to Treatment, and Retention Rates — 40; 33; 15; 32 Participants
Early Phase 1 N=25 Imaging the Neurochemistry of Drug Addiction With PET
Smoking · Cannabis
Primary: Change in Dopamine Levels at Baseline and After Drug of Dependence Administration as Confirmed by PET Images. — 0.0388; 0.033; 0.0285; 0.0368 mm^3
N/A N=186 Preventing Addiction Related Suicide (PARS)
Suicide · Substance-Related Disorders
Primary: PARS Help-Seeking Scale — 0.57; 0.53 units on a scale
Phase 3 N=21 Neuroimaging Predictors of Relapse During Treatment for Opiate Dependence
Opioid Addiction
Primary: Changes in Resting State Disorganization Between Baseline and One Week by Person by Lapsed Category — 0.315; 0.328; 0.384; 0.394 Mean default mode network (DMN) z-scores
Phase 2 N=107 Interactive Motivational Media for Perinatal Drug Abuse - 3
Substance-Related Disorders
Primary: Number of Participants With Drug Use at 3 Months — 49; 48 participants
N/A N=150 Intensive Models of HCV Care for Injection Drug Users
Hepatitis C · Medication Adherence
Primary: Electronically Monitored Medication Adherence — 86; 80; 75 Percentage of medication taken